E

    Estrella Immunopharma Inc. (ESLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.72
    +0.02 (+2.82%)

    Market Cap: $31.54M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(6/8)
    Avg Surprise
    +29.82%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.08+0.0%
    7d ago$-0.08+0.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range$0.00 - $0.00
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.00---
    Sep 26EST
    		-$-0.08---
    Jun 26
    Reported Aug 13
    		$-0.05$-0.09+44.44%Beat+66.7%
    Mar 26
    Reported May 15
    		$-0.05N/A+73.68%Beat+16.7%
    Dec 25
    Reported Mar 18
    		$-0.01N/A+85.71%Beat+66.7%
    Sep 25
    Reported Nov 12
    		$-0.13$-0.07-85.71%Miss-44.4%
    Jun 25
    Reported Aug 11
    		$-0.15$-0.12-25.00%Miss-39.0%
    Mar 25
    Reported May 14
    		$-0.06$-0.11+45.45%Beat-354.5%
    Dec 24
    Reported Feb 15
    		$-0.03N/A+75.00%Beat-3.4%
    Sep 24
    Reported Nov 14
    		$-0.09$-0.12+25.00%Beat+94.9%
    Jun 24
    Reported Sep 27
    		$-0.11N/AN/ABeat-231.0%
    Mar 24
    Reported May 14
    		$-0.01N/AN/ABeat+51.5%
    Dec 23
    Reported Feb 14
    		$-0.03N/AN/ABeat+73.6%
    Sep 23
    Reported Sep 30
    		$-1.78N/AN/ABeat-2861.5%
    Jun 23
    Reported Jun 30
    		$-0.03N/AN/ABeat+45.7%
    Mar 23
    Reported Jun 28
    		$-0.03N/AN/ABeat-36.0%
    Dec 22
    Reported Mar 29
    		$-0.11N/AN/ABeat+8.3%
    Sep 22
    Reported Nov 14
    		$-0.06N/AN/ABeat-200.0%
    Jun 22
    Reported Sep 28
    		$-0.06N/AN/ABeat-
    Mar 22
    Reported Jun 29
    		$-0.02N/AN/ABeat-
    Dec 21
    Reported Mar 30
    		$-0.12N/AN/ABeat-
    Sep 21
    Reported Nov 10
    		$-0.02N/AN/ABeat-
    Jun 21
    Reported Sep 28
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.02EV/EBITDA-3.07x
    Price/FCF-3.32xFCF Yield-30.10%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-268.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.20xQuick Ratio0.20x
    Trading Statistics
    Beta0.89Avg Volume30.03K
    52-Week High$3.1552-Week Low$0.63

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.73
    SMA 20$0.73
    SMA 50$0.81
    SMA 200$1.23
    EMA 10$0.73
    EMA 20$0.74
    EMA 50$0.83
    EMA 200$1.10

    MACD

    Line: -0.02Signal: -0.03Hist: 0.01

    ADX

    ADX: 17.4+DI: 15.3-DI: 19.0

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down96.0
    PSAR$0.85

    Bollinger Bands

    Upper Band$0.76
    Lower Band$0.70
    %B Position804%(Upper)
    Band Width0.42

    RSI (14-Day)

    Neutral
    43.2

    Momentum Oscillators

    Stoch %K33.3
    Stoch %D28.0
    Williams %R-55.6
    ROC (10d)-4.6%
    Momentum-0.04
    CCI (20d)-141.8
    MFI (14d)45.5

    Volatility Measures

    ATR (14d)$0.07(9.0%)
    StdDev (20d)0.01
    Hist Vol42.9%(High)

    Volume Flow

    VWAP$0.70
    OBV2.8M
    AD Line-6.2M
    CMF (20d)-0.401

    Volume Metrics

    Avg Vol (20d)30.2K
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.74

    Pivot Points

    R3$0.89
    R2$0.82
    R1$0.77
    Pivot Point$0.70
    S1$0.64
    S2$0.57
    S3$0.51

    Advanced Oscillators

    TSI-16.99
    Ultimate Osc43.4
    KST-84.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0N/A$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Operating Expenses$2.08M$2.29M$613,199$4.80M$5.54M$2.10M$1.05M$3.38M$3.95M$469,530$1.02M$1.87M
    R&D$1.40M$1.40M$25,414$4.15M$4.66M$1.41M$32,566$2.83M$3.52M$25,000$75,459$483,466
    SG&A$684,015$891,789$587,785$648,507$883,727$694,110$1.02M$550,737$424,447$444,530$945,165$1.39M
    Operating Income$-2,084,247$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-469,530$-1,020,624$-1,870,497
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$222,092$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,306,339$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-469,530$-1,020,624$-1,870,497
    Income Tax Expense$0$0$-25$0$850$13$63$1,625$1,625$39,586$-122,089$-41,581
    Net Income$-2,306,339$-2,292,064$-613,174$-4,801,149$-5,544,878$-2,104,311$-1,050,290$-3,376,737$-3,951,072$-469,530$-1,020,624$-1,870,497
    EBITDA$-2,084,247$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-469,530$-898,539$-1,828,913
    EBITN/AN/AN/AN/A$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-429,944$-1,020,624$-1,870,497
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ESLA

    News

    Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard

    Estrella Immunopharma (ESLA) has been notified by Nasdaq of its failure to meet the $1.00 minimum bid price requirement. The company has until February 16, 2027, to regain compliance, with a possibility of an additional 180-day grace period before facing delisting. This disclosure is based on an SEC filing from August 21, 2026.

    TradingView•8/21/26•
    Bearish

    ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half

    Armistice Capital, LLC has significantly reduced its stake in Estrella Immunopharma Inc (NASDAQ:ESLA) by nearly half, selling 2,047,591 shares at $1.04 each. This transaction leaves Armistice Capital with 4.99% of ESLA's outstanding shares, indicating a reassessment of the biopharmaceutical company's near-term prospects. Estrella Immunopharma, a clinical-stage company with a low GF Score and negative financial metrics, has seen its stock decline substantially since its IPO, raising concerns for potential investors.

    GuruFocus•8/21/26•
    Neutral

    Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake

    Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. (ESLA) common stock. This translates to 2,051,409 shares, over which they hold shared voting and dispositive power. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as investment manager.

    Stock Titan•8/14/26•
    Neutral

    Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary

    Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a partnership with Eureka, and successful capital raises to fund operations.

    TradingView•8/13/26•
    Neutral

    Estrella adds fourth site to EB103 lymphoma trial

    Estrella Immunopharma Inc. has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103, an investigational T-cell therapy for B-cell non-Hodgkin's lymphoma. This expansion aims to evaluate the therapy's safety and efficacy, with data expected to inform the pivotal trial strategy for EB103. The therapy utilizes ARTEMIS technology from Eureka Therapeutics and targets CD19-positive cancer cells.

    Investing.com•8/11/26•
    Bullish

    Frequently Asked Questions About ESLA

    Does ESLA pay dividends?
    Estrella Immunopharma Inc. (ESLA) does not currently pay a regular dividend.
    What is ESLA's market cap?
    Estrella Immunopharma Inc. (ESLA) has a market capitalization of $31.54M with a current stock price of $0.72.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In